Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis optica spectrum disorders—from mechanisms to trials. Nat Rev Neurol. 2021;17(12):759–73.
Article CAS PubMed Google Scholar
Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1–16.
Article CAS PubMed Google Scholar
Collongues N, Ayme-Dietrich E, Monassier L, et al. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs. 2019;79(2):125–42.
Article CAS PubMed Google Scholar
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.
Article PubMed PubMed Central Google Scholar
Costello F, Burton JM. Contemporary management challenges in seropositive NMOSD. J Neurol. 2022;269(10):5674–81.
Article PubMed PubMed Central Google Scholar
Valencia-Sanchez C, Wingerchuk DM. Emerging targeted therapies for neuromyelitis optica spectrum disorders. BioDrugs. 2021;35(1):7–17.
Article CAS PubMed Google Scholar
Lana-Peixoto MA, Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines. 2019;7(2):42.
Article CAS PubMed PubMed Central Google Scholar
Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.
Article PubMed PubMed Central Google Scholar
Uzawa A, Mori M, Ito M, et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol. 2009;256(12):2082–4.
Article CAS PubMed Google Scholar
Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1): e311.
Chihara N, Aranami T, Oki S, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS ONE. 2013;8(12): e83036.
Article PubMed PubMed Central Google Scholar
Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013;70(3):394–7.
Roche Registration GmbH. Enspryng 120 mg solution for injection in pre-filled syringe. 2021. https://www.ema.europa.eu/. Accessed 13 Feb 2023.
Roche Registration GmbH. Enspryng® 120 mg solution, for subcutaneous use 2022. https://dailymed.nlm.nih.gov/. Accessed 13 Feb 2023.
Lennon-Chrimes S, Baumann HS, Klingelschmitt G, et al. Characterisation of the PK and PD of satralizumab, a recycling antibody, to support Q4W dosing in patients with NMOSD [abstract no. 1483]. Neurology. 2020;94(15 Suppl.):1483.
Hemingway C, Baumann HS, Kou XJ, et al. Adolescents with NMOSD achieved similar exposures and favorable safety profile when treated with the adult satralizumab dosing regimen [abstract no. 1492]. Neurology. 2020;94(15 Suppl.):1492.
Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–24.
Article CAS PubMed Google Scholar
Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–12.
Article CAS PubMed PubMed Central Google Scholar
Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–9.
Article CAS PubMed Google Scholar
Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in AQP4-IgG–seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023;10(1): e200071.
Yamamura T, Weinshenker B, Yeaman MR, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66: 104025.
Article CAS PubMed Google Scholar
Traboulsee A, Yeaman MR, Weinshenker BG, et al. Satralizumab in patients with neuromyelitis optica spectrum disorder and concomitant autoimmune disease [abstract no. 4118]. Neurology. 2021;96(15 Suppl.):4118.
Alexion Pharmaceuticals. Soliris 300 mg concentrate for solution for infusion. 2021. https://www.ema.europa.eu/. Accessed 13 Feb 2023.
Horizon Therapeutics. Uplizna 100 mg concentrate for solution for infusion. 2022. https://www.ema.europa.eu/. Accessed 13 Feb 2023.
Bennett JL, Fox E, Greenberg B, et al. Long-term efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): results from the phase 3 SAkura studies [abstract no. P277]. Mult Scler J. 2022;28(1 Suppl.):20–214.
Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60–7.
Article CAS PubMed Google Scholar
Frampton JE. Eculizumab: a review in neuromyelitis optica spectrum disorder. Drugs. 2020;80(7):719–27.
Article CAS PubMed PubMed Central Google Scholar
Nie T, Blair HA. Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs. 2022. https://doi.org/10.1007/s40263-022-00949-7.
Article PubMed PubMed Central Google Scholar
Traboulsee A, Fujihara K, Kim HJ, et al. SAkuraBONSAI: a prospective, open-label study of satralizumab investigating novel imaging, biomarker, and clinical outcomes in patients with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) [abstract no. P15-1.002]. Neurology. 2022;98(18 Suppl.):P15-1.002.
留言 (0)